In Silico Drug Testing and Optimization, Coupling Physical-Based Modeling and Machine Learning

Guest Editors:

Prof. Dr. Nenad D. Filipović
1. Faculty of Engineering, University of Kragujevac, 34000 Kragujevac, Serbia
2. BIOIRC, Bioengineering Research and Development Center, 34000 Kragujevac, Serbia

Prof. Dr. Zoran Markovic
Department for Natural and Mathematical Sciences, Institute for Information Technologies Kragujevac, University of Kragujevac, Jovana Cvijića bb, 34000 Kragujevac, Serbia

Deadline for manuscript submissions:
closed (29 February 2024)

Message from the Guest Editors

Dear Colleagues,

In silico numerical simulations may provide additional information regarding the mechanisms guiding drug testing and optimization. The aim of this Special Issue is to use physical-based modeling methods such as continuum computational fluid dynamics (CFD), computational solid dynamics (CSD), discrete molecular dynamics (MD), dissipative particle dynamics (DPD), discrete phase modelling (DPM) and physiologically based pharmacokinetic (PBPK) coupled with machine learning to better describe drug transfer and distribution inside organs. The design of new prospective drugs, as well as carriers for their successful delivery, will be welcomed. It focuses on cardiovascular and lung biomechanics but is not limited to other organs. A comprehensive list of patient-specific features such as genetic, biological, pharmacologic and cellular aspects can be taken into account. The aim is to avoid adverse effects, drug interactions, prevent sudden patient death and shorten the time between drug treatment commencement and the achievement of desired results. In silico methods could open a new avenue for medical device and drug testing, reducing the use of real clinical trials.

Special Issue

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us